CHRS (Coherus Oncology, Inc.) is set to announce its Q2'26 results on July 30, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).
For Q2'26, revenue estimate is 14.41 million USD with EPS (earnings per share) anticipated at (0.24) USD. Learn more details at .
Revenue & EPS values are provided in USD
| Q2'25Q3'25Q4'25Q1'26Q2'26 | |||||
| Revenue Reported10.25 M11.57 M12.75 M12.31 M— | Revenue Estimate9.35 M13.36 M13.91 M14.22 M14.41 M | Revenue Surprise+9.64%-13.41%-8.37%-13.42% | EPS Reported(0.39)(0.31)(0.39)(0.27) | EPS Estimate(0.22)(0.35)(0.36)(0.26)(0.24) | EPS Surprise-77.00%+12.41%-9.83%-2.53% |